(Fundação de Amparo à Pesquisa do Estado de São Paulo) Tests using mice employed an experimental drug that stimulates a specific type of nicotinic receptor in immune cells; researchers attested the reversion of the inflammation condition. The results of the drug were surprising, given the fact that it simulates acetylcholine, a bronchoconstrictor neurotransmitter inhibited by asthma and DPOC's best-known treatments
